The great mystery drug. Much like Becca said I also am hoping for a late November release of Antegren data with the FDA approval. I came across this article today “Elan, Biogen Jump as Drug Shines in Trial”. While I could care less about their share price, etc. I did find two things of interest. The continued thought of a November 25th approval from the FDA – which I suspect they would have to release specific performance data to get anyone to try it at the same time. The item of even bigger interest was that they are claiming a 66% reduction in relapse as compared to Rebif which I believe is in the mid 40’s. Hopefully Antegren will do much better as a combination therapy. I’ll be even more interested to see how this all pans out at the end of the Phase III trial next year.